Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
ChemAxon will provide the core tools to support the pan European initiative.

ChemAxon and the European Lead Factory have announced that ChemAxon will provide the core tools and leads the development of the informatics platform to support the pan European initiative.

ChemAxon will be building a portal to support the crowd-sourcing initiative using its core JChem Base and Marvin components.

The scientific decision process involved in selecting the right proposals from those submitted will be supported by ChemAxon’s Discovery Toolkit, including various fingerprints and physico-chemical property predictors.

The portal will also offer a way for submitters to keep track of their submission’s status and for the consortium’s selection committee to score and analyze submitted proposals.

The Innovative Medicines Initiative (IMI), the world’s largest public-private initiative in the field of pharmaceutical research aims to create a new and unique collaboration of public and private sector.

The research program of up to EUR196 million and named the European Lead Factory, involving small and medium-sized enterprises (SMEs), academic institutions and large pharmaceutical companies, aims to improve the competitiveness of the European pharmaceutical industry, accelerate the drug development process, and strives to develop safer, more effective drugs.

The European Lead Factory was launched by an international consortium of 30 partners, with the only Hungarian participant being ChemAxon Ltd. This partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates unprecedented opportunities for the discovery of new medicines through access to a collection of small molecules contributed by pharmaceutical companies, and a newly synthesized compound collection built by the SMEs and academic institutions.

As a result of this partnership, the new compound library consisting of up to half a million compounds will be accessible to all project partners and to public organizations.

Screening of this compound collection will be performed within the pharmaceutical companies and by a newly established European Screening Centre, which will run state of the art facilities in Scotland and the Netherlands to handle logistics and screening of compound libraries.

If the project proves successful during its initial five year funding period, the partnership aims for a sustainable role in drug discovery in Europe.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ChemAxon Extends Free Service with Predicted Data and User Customization
The new features help users understand better the chemical structure with more predicted properties and a customizable layout.
Monday, August 23, 2010
Broad Institute Acquires License to all ChemAxon Products and Deploys Across Chemical Biology Platform
License covers ChemAxon’s platform, discovery toolkits and desktop applications for institute-wide use.
Friday, August 20, 2010
ChemAxon Announces new CEO and Head of R&D
Company increases its focus on business development and market position with new appointments.
Tuesday, May 13, 2008
Migrating Chemical Information to New Architectures
New ChemAxon whitepaper discusses the drivers behind the increasing number of pharma and biotech companies moving from traditional proprietary chemical information systems to modern alternatives.
Monday, January 29, 2007
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos